The Korean journal of internal medicine

  • 제28권3호
  • /
  • Pages.297-299
  • /
  • 2013
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Design of precise third-line therapy for gastric cancer: target or chemotherpy?

  • Cho, Jae Yong (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • 발행 : 2013.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  2. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168. https://doi.org/10.1023/A:1008243606668
  3. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90. https://doi.org/10.1016/j.clon.2004.10.006
  4. Park JS, Lim JY, Park SK, et al. Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011;43:236-243. https://doi.org/10.4143/crt.2011.43.4.236
  5. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer- -a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
  6. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518. https://doi.org/10.1200/JCO.2011.39.4585
  7. Ford H, Marshall A, Wadsley J, et al. COUGAR-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma [abstract]. J Clin Oncol 2013;31(4 Suppl):LBA4. https://doi.org/10.1200/jco.2013.31.4_suppl.lba4
  8. Fuchs CS, Tomasek J, Cho JY, et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine- containing combination therapy [abstract]. J Clin Oncol 2013;31(4 Suppl):LBA5. https://doi.org/10.1200/JCO.2012.43.5784
  9. Lee JH, Kim SH, Oh SY, et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J Intern Med 2013;28:314-321. https://doi.org/10.3904/kjim.2013.28.3.314
  10. Cho JY, Lim JY, Cheong JH, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011;17:1850-1857. https://doi.org/10.1158/1078-0432.CCR-10-2180